A new nephelometric technique to measure C3d as an indicator of complement activation, is described. C3d is isolated at high concentration of polyethyleneglycol (PEG), incubated with commercially available anti-C3d antiserum at a final concentration of 2*5% PEG and then measured in a Behring Laser Nephelometer.
In contrast to previously available techniques our assay detects the low concentrations of C3d present in all normal subjects, which result from the continuous C3 catabolism occurring in vivo.
We have also measured C3d blood concentrations in a large number of patients with diseases associated with complement activation. Raised C3d concentrations were found in 68% of rheumatoid arthritis, 57% of primary biliary cirrhosis, 38% of chronic active hepatitis, 100% of Gram-negative bacteraemia and 100% of malaria.
The nephelometric technique has proved to be sensitive, economical and fast, and could be adapted for routine determination of C3d blood concentrations to monitor disease activity and response to treatment.
In a number of immunologically mediated disorders, the occurrence and degree of tissue damage depends on the activation of the complement (C') system.'-3
To detect and measure C' activation is useful not only for assessment of disease activity but also to monitor response to treatment.
The complement cascade can be activated via a "classical" pathway following an antigen-antibody reaction or via an "alternative" pathway which usually does not require an antibody as triggering factor.46 Both pathways converge at the level of C3 whose split products reflect C' activation by either pathway. C3 is broken down by C3 convertases to a small C3a and a large C3b fragment. C3b is inactivated by C3b inhibitor (factor I) to form C3bi. A further trypsin-like enzymatic activity produces C3c and C3d fragments (Fig. 1) .
The eletrophoretical mobility of C3 fragments differs from that of native C3, and this has been used to assess C' activation. Several techniques have been devised which exploit this different mobility of the C3 fragments, and include immunoelectrophoresis,7 crossed immunoelectrophoresis,8 counter immunoelectrophoresis,9 and immunofixation.'0 All these methods are mostly qualitative, timeAccepted for publication 31 January 1983 793 consuming and hardly suitable for screening large batches of samples. Furthermore, some-that is, crossed immunoelectrophoresis and immunoelectrophoresis-require large amounts of antisera.
An alternative approach has been reported by Perrin et al" who have investigated the solubility of several C' components and fragments at increasing concentrations of polyethyleneglycol (PEG). These authors have shown that of the C3 split products only C3d was present in solution at concentrations above 11% of PEG: this fragment was measured by radial immunodiffusion, a technique that requires at least 48 h before reading.
We decided to measure C3d by laser nephelometry, a technique faster and more sensitive than radial immunodiffusion. C3d was chosen as measure of C' activation for two reasons: (i) the presence of C3d in the circulation is unequivocal proof of C' activation; (ii) C3d in contrast to other C3 breakdown products is metabolised slowly'2 and thus provides a longer lasting trace of C' activation. After attaining optimal assay conditions with normal human plasma, a normal range in a large control population has been established. We (1/.) C3d decreased the sensitivity of the assay while no read- Fig. 4 Effect ofdifferent concentrations ofPEG on C3d ing was obtained when PEG was not added (Fig. 4) . detection using anti-C3d antiserum diluted 1/5.
Comparable results were obtained when readings were performed at times varying between 15 and 180 min; we found it more convenient to read after (1/.) C3d
Low yet measurable concentrations of C3d were mal+2 SD provided the upper limit of normal for the assay (Fig. 6 ). C3d concentrations in patients suffering from conditions where complement is expected to be activated via either pathway is shown in Fig. 6 
